Actuate Therapeutics Inc (ACTU)

$4.71 -0.03 (-0.63%)
Market Cap 110.17M
Revenue (ttm) 0.00
Net Income (ttm) -27.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 60,800
Avg Vol 83,534
Day's Range N/A - N/A
Shares Out 23.24M
Stochastic %K 11%
Beta -0.15
Analysts Strong Sell
Price Target $25.00

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and color...

Industry: Biotechnology
Sector: Healthcare
Phone: 817 887 8455
Address:
1751 River Run, Suite 400, Fort Worth, United States
BioTuesdays
BioTuesdays Jan. 21 at 7:22 PM
$ACTU has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer https://biotuesdays.com/2026/01/21/actuate-to-advance-elraglusib-tablet-to-phase-1-2-program-in-refractory-cancers/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 1:48 PM
$ACTU Current Stock Price: $5.31
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 14 at 12:54 AM
$ACTU I really think this is a sleeper. Can someone I follow let me know if I’m missing something. Thanks!!
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 13 at 3:40 PM
$XAIR, $UAVS, a sleeper you may want to watch is $ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 2:07 PM
$ACTU
0 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:57 PM
$ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 1:57 PM
$ACTU might want to take a look. Great news out. FYI
1 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:56 PM
$ACTU https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html?_gl=1*1s3ds1o*_up*MQ..*_ga*MTgzMzczNTcwMC4xNzY4MjI2MTE4*_ga_ERWPGTJ5X8*czE3NjgyMjYxMTgkbzEkZzAkdDE3NjgyMjYxMTgkajYwJGwwJGgw
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 12 at 1:45 PM
$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
0 · Reply
_Jean123
_Jean123 Jan. 10 at 10:57 PM
🎯 $ACTU - THE NEXT BIOTECH MOONSHOT? 🚀 🔹 Analyst Target: $35.00 (Lucid Capital Markets) 🔹 Current Price: ~$6.14 (Upside +430%) 🔹 The Catalyst: ASCO GI 2026 data confirmed 43% reduction in death risk for Pancreatic Cancer. 🧬 🔹 Scarcity: Ultra Low Float (<5M effective). High Institutional interest. 💎 This isn't just a stock; it's a science-backed revolution. Monday gap-up loading... 📈 📑 Full Analyst Report ($35 PT): https://www.investing.com/news/analyst-ratings/actuate-therapeutics-stock-gets-buy-rating-after-positive-phase-1-results-93CH-4433361
0 · Reply
Latest News on ACTU
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Jan 12, 2026, 8:45 AM EST - 19 days ago

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Jan 6, 2026, 8:45 AM EST - 25 days ago

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

Dec 18, 2025, 8:45 AM EST - 6 weeks ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Sep 22, 2025, 8:45 AM EDT - 4 months ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Sep 10, 2025, 8:31 AM EDT - 5 months ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2025, 4:07 PM EDT - 5 months ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Aug 6, 2025, 8:45 AM EDT - 6 months ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Jul 17, 2025, 8:45 AM EDT - 7 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Jun 24, 2025, 9:15 AM EDT - 7 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Jun 20, 2025, 8:45 AM EDT - 8 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 8:30 AM EDT - 8 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 31, 2025, 4:30 PM EDT - 8 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 9 months ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:24 AM EDT - 10 months ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Apr 17, 2025, 8:00 AM EDT - 10 months ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Feb 6, 2025, 8:00 AM EST - 1 year ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Dec 17, 2024, 8:28 AM EST - 1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Oct 29, 2024, 6:39 PM EDT - 1 year ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 9:10 AM EDT - 1 year ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Aug 17, 2024, 5:10 AM EDT - 1 year ago

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

HCAI TDTH WRD YXT

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics Announces Pricing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

Aug 3, 2024, 12:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

GFL OSTX

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ARDT ARTV CON LINE OS QMMM TWFG

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

May 28, 2024, 5:34 PM EDT - 1 year ago

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

BioTuesdays
BioTuesdays Jan. 21 at 7:22 PM
$ACTU has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer https://biotuesdays.com/2026/01/21/actuate-to-advance-elraglusib-tablet-to-phase-1-2-program-in-refractory-cancers/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 1:48 PM
$ACTU Current Stock Price: $5.31
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 14 at 12:54 AM
$ACTU I really think this is a sleeper. Can someone I follow let me know if I’m missing something. Thanks!!
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 13 at 3:40 PM
$XAIR, $UAVS, a sleeper you may want to watch is $ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 2:07 PM
$ACTU
0 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:57 PM
$ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 1:57 PM
$ACTU might want to take a look. Great news out. FYI
1 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:56 PM
$ACTU https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html?_gl=1*1s3ds1o*_up*MQ..*_ga*MTgzMzczNTcwMC4xNzY4MjI2MTE4*_ga_ERWPGTJ5X8*czE3NjgyMjYxMTgkbzEkZzAkdDE3NjgyMjYxMTgkajYwJGwwJGgw
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 12 at 1:45 PM
$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
0 · Reply
_Jean123
_Jean123 Jan. 10 at 10:57 PM
🎯 $ACTU - THE NEXT BIOTECH MOONSHOT? 🚀 🔹 Analyst Target: $35.00 (Lucid Capital Markets) 🔹 Current Price: ~$6.14 (Upside +430%) 🔹 The Catalyst: ASCO GI 2026 data confirmed 43% reduction in death risk for Pancreatic Cancer. 🧬 🔹 Scarcity: Ultra Low Float (<5M effective). High Institutional interest. 💎 This isn't just a stock; it's a science-backed revolution. Monday gap-up loading... 📈 📑 Full Analyst Report ($35 PT): https://www.investing.com/news/analyst-ratings/actuate-therapeutics-stock-gets-buy-rating-after-positive-phase-1-results-93CH-4433361
0 · Reply
_Jean123
_Jean123 Jan. 9 at 6:44 PM
$ACTU THE DIP AT $6.00! 🚀🚀🚀 Don't let the market makers shake you out before the 1:30 PM poster release. 37% death risk reduction is a game-changer in this sector. $ACTU is literally a ticking time bomb with that tiny float. If the oral presentation tonight is a hit, $20 is the floor. HODL tight! 🔥📈 #ASCOGI2026 #ACTU
1 · Reply
Bulldog1776
Bulldog1776 Jan. 8 at 6:42 PM
$ACTU these oral presentations are great and all but I’ve seen in the past where the stock doesn’t really move much unless there is a PR or conference call. What do you all think about the upcoming presentations and stock price?
2 · Reply
G101SPM
G101SPM Jan. 7 at 8:17 PM
#SHOWTIME American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 8-10) Scheduled to appear: $ACTU, $CATX, $JAZZ, $ZYME
0 · Reply
BioTuesdays
BioTuesdays Jan. 7 at 6:33 PM
$ACTU has announced results from the phase 1 portion of its Actuate-1902 Phase 1/2 clinical study evaluating elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or with cyclophosphamide plus topotecan in pediatric patients with refractory malignancies https://biotuesdays.com/2026/01/07/actuate-announces-positive-phase-1-elraglusib-results-in-pediatric-cancer/
0 · Reply
topstockalerts
topstockalerts Jan. 6 at 3:49 PM
Actuate Therapeutics reported encouraging Phase 1 results for elraglusib in difficult-to-treat pediatric cancers. The trial showed meaningful clinical activity, including two complete metabolic responses in relapsed/refractory metastatic Ewing sarcoma patients and a complete response in a relapsed/refractory metastatic neuroblastoma patient. In the open-label, multicenter study of 40 pediatric patients with relapsed or refractory cancers, 15 showed clinical responses or disease control. Notably, 10 of 19 patients treated with elraglusib in combination with cyclophosphamide/topotecan achieved positive outcomes. The company highlighted cases of heavily pretreated patients achieving substantial tumor reduction and complete bone marrow response. Actuate plans to advance elraglusib’s clinical development in Ewing sarcoma and potentially neuroblastoma in 2026. $ACTU
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 6 at 2:05 PM
$ACTU (+7.7% pre) Actuate reports responses in pediatric cancer trial https://ooc.bz/l/88737
0 · Reply
Smellmahass
Smellmahass Jan. 6 at 12:47 AM
$ACTU So they released this pancreatic data already? Whats this data on the 9th?
1 · Reply
OnlyGB
OnlyGB Jan. 5 at 12:31 PM
$DRTS leading the charge at ASCO GI 2026 (Jan 8-10) with two Alpha DaRT abstracts on pancreatic cancer pilots – feasibility/safety/efficacy + immune markers. Building momentum in this innovative alpha-radiation space for tough cancers. Also watching related plays like $ACTU (Phase 2 data oral/poster), $AMIX (pain mitigation poster), and $BFRG (AI-subtyping poster). Big week ahead for pancreatic oncology!
1 · Reply
JKtech
JKtech Jan. 5 at 11:17 AM
ASCO GI 2026: What to watch The data is LIVE and Alpha Tau is the standout. Two massive abstracts prove Alpha DaRT is the next frontier in internal oncology: $DRTS - Abstract #1 shows breakthrough safety in advanced Pancreas cancer treatment. Ultra-high dose precision in "inoperable" tumors. Abstract #2 highlights immune markers-turning the tumor into its own vaccine. 31% insider skin-in-the-game + $12 analyst PT. $ACTU - Jan 9 Oral session on Elraglusib. Risk of death reduced by 37% in early looks. The market wants the full survival curves. $RNXT - Abstract #732. Proving their TAMP platform hits the tumor harder with fewer side effects than systemic chemo. $ALPMY - Late-breaking data on Zolbetuximab. Setting the "Precision" ceiling for the Gl sector
1 · Reply
CapitalCycleNavigator
CapitalCycleNavigator Dec. 27 at 7:59 AM
$ACTU Positioning is increasingly shaped by how predictably management executes. Cash discipline will likely dictate investor patience. Credible progress tends to compress risk premiums. Execution quality becomes the defining catalyst from here.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 19 at 10:56 PM
$ACTU
0 · Reply
TwongStocks
TwongStocks Dec. 18 at 1:46 PM
$ACTU Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 https://www.globenewswire.com/news-release/2025/12/18/3207741/0/en/Actuate-Therapeutics-Phase-2-Metastatic-Pancreatic-Cancer-Data-Selected-for-Oral-and-Poster-Presentation-at-ASCO-GI-2026.html Oral Presentation Title: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). Poster Presentation Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B Phase 2 study.
0 · Reply